New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Semax

Pancragen vs Semax

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Cognitive Enhancement
Semax
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Semax is a synthetic heptapeptide derived from ACTH developed in Russia. It is a potent nootropic that enhances memory, focus, and provides neuroprotection. Approved in Russia for cognitive disorders, stroke recovery, and traumatic brain injury.
Half-Life
Short (minutes); sustained gene-regulatory effects
Minutes (but effects persist for hours via BDNF induction)
Admin Route
SubQ, Oral
Intranasal, SubQ
Research
Typical Dose
10 mg per day
0.25–1 mg (250–1000 mcg)
Frequency
Daily for 10–30 days
1–2 times daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Enhances memory and learning
  • Improves focus and concentration
  • Increases mental energy and motivation
  • Provides neuroprotection via BDNF and NGF upregulation
  • Reduces cognitive decline
  • May alleviate ADHD symptoms
  • Supports recovery from brain injury and stroke
  • Fast-acting — effects within 30–60 minutes
  • Approved in Russia for cognitive disorders and stroke recovery
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Headache (rare, often from higher doses)
  • Anxiety or overstimulation at high doses
  • Sleep disruption if dosed too late
  • Irritability (uncommon)
Stacks With